Skip to content

TO Evaluate The Efficacy of Asgand in Health Promotion in Elderly

A randomized, placebo-controlled trial on Asgand for promoting health in the elderly population - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/098726
Enrollment
50
Registered
2025-12-10
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Z08- Encounter for follow-up examination after completed treatment for malignant neoplasm Health Condition 2: Z008- Encounter for other general examination Health Condition 3: Z008- Encounter for other general examination

Interventions

Intervention1: Asgand In powder form oraally 3gms BD for 60 days: Root of Asgand( withania somenifera) in powdered form orally 3gm BD For 60 Days Control Intervention1: Placebo: Roasted Wheat flour 3g

Sponsors

National Institute of unani medicine banglore
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age above 60 years of age 2)Subjects of either sex 3)Persons with more than 3 signs from the below will be included in the study a.Patient with baseline score of 7 or more than 7 on frailty assessment screening tool (FAST) b)History of weight loss c)Loss of appetite d)Frequency of infection e)Slow walking/gait speed f)Subjects with low mental score

Exclusion criteria

Exclusion criteria: 1)Subjects below 60 years of age 2)uncontrolled diabetes mellitus and hypertension 3)Chronic obstructive pulmonary disease (COPD) 4)Non-compliance with therapy 5)Patients with other chronic diseases like cancer and AIDS 6)Unstable cardiac or renal disease 7)History of surgery within one year 8)Consumption of any dietary or nutritional supplements multivitamins at least one month before the study 9)Mini-mental State Examination (MSME) score of less than 20

Design outcomes

Primary

MeasureTime frame
Change in Frailty score (FAST) change in appetite score change in body weight change in grip strength change in LIPID profile Timepoint: At baseline , 15th day, 30th day, 45th day,and on 60th day

Secondary

MeasureTime frame
Change in Quality of life Score( SF-12) Change in sleep Quality score(PSQI) Change in cognitive performance(MSME score)Timepoint: Baseline (0th day) 60th day

Countries

India

Contacts

Public ContactShaikh Mariya Mumtaz

Institute of Unani Medicine Bangalore

Kzarnigar15@gmail.com7483244027

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026